Activation and inhibition of the human α7 nicotinic acetylcholine receptor by agonists

Neuropharmacology

Volumn 37, Issue 9, 1998, Pages 1095-1102

  Briggs, Clark A ^a   McKenna, David G ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Acetylcholine; Acetylcholine nicotinic receptor (nAChR)

Indexed keywords

1,1 DIMETHYL 4 PHENYLPIPERAZINIUM IODIDE; 2 METHYL 3 (2 PYRROLIDINYLMETHOXY)PYRIDINE; ACETYLCHOLINE; COTININE; LOBELINE; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; IN VITRO STUDY; NONHUMAN; OOCYTE; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; XENOPUS;

ACETYLCHOLINE; ANIMALS; COTININE; DIMETHYLPHENYLPIPERAZINIUM IODIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LOBELINE; MEMBRANE POTENTIALS; NICOTINE; NICOTINIC AGONISTS; OOCYTES; PATCH-CLAMP TECHNIQUES; RECEPTORS, NICOTINIC; RNA; XENOPUS;

EID: 0032440954     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(98)00110-5     Document Type: Article

References (55)

1. Albuquerque, E.X., Alkondon, M., Pereira, E.F.R., et al., 1997. Properties of neuronal nicotinic acetylcholine receptors: pharmacological characterization and modulation of synaptic function. J. Pharmacol. Exp. Ther. 280, 1117-1136.
2. Alkondon, M., Pereira, E.F.R., Cortes, W.S., Maelicke, A., Albuquerque, E.X., 1997. Choline is a selective agonist of α7 nicotinic acetylcholine receptors in the rat brain neurons. Eur. J. Neurosci. 9, 2734-2742.
3. Bartrup, J.T., Newberry, N.R., 1996. Electrophysiological consequences of ligand binding to the desensitized 5-HT3 receptor in mammalian NG108-15 cells. J. Physiol. (London) 490, 679-690.
4. Benowitz, N.L., Jacob, P. III, 1993. Nicotine and cotinine elimination pharmacokinetics in smokers and nonsmokers. Clin. Pharmacol. Ther. 53, 316-323.
5. Bertrand, D., Changeux, J.P., 1995. Nicotinic receptor: an allosteric protein specialized for intercellular communication. Semin. Neurosci. 7, 75-90.
6. Briggs, C.A., McKenna, D.G., Piattoni-Kaplan, M., 1995. Human α7 nicotinic acetylcholine receptor responses to novel ligands. Neuropharmacology 34, 583-590.
7. Briggs, C.A., McKenna, D.G., 1996. Effect of MK-801 at the human α7 nicotinic acetylcholine receptor. Neuropharmacology 35, 407-414.
8. Brioni, J.D., O'Neill, A.B., Kim, D.J.B., Decker, M.W., 1993. Nicotinic receptor agonists exhibit anxiolytic-like effects on the elevated plus-maze test. Eur. J. Pharmacol. 238, 1-8.
9. Chen, D.N., Patrick, J.W., 1997. The α-bungarotoxin binding nicotinic acetylcholine receptor from rat brain contains only the α7 subunit. J. Biol. Chem. 272, 24024-24029.
10. 4 25-35, mimics the function of substance P on modulation of nicotine-evoked secretion and desensitization in cultured bovine adrenal chromaffin cells. J. Neurochem. 60, 1163-1166.
11. Court, J.A., Perry, E.K., Spurden, D., Lloyd, S., Gillespie, J.I., Whiting, P., Barlow, R., 1994. Comparison of the binding of nicotinic agonists to receptors from human and rat cerebral cortex and from chick brain (α4β2) transfected into mouse fibroblasts with ion channel activity. Brain Res. 667, 118-122.
12. Curzon, P., Kim, D.J.B., Decker, M.W., 1994. Effect of nicotine, lobeline, and mecamylamine on sensory gating in the rat. Pharmacol. Biochem. Behav. 49, 877-882.
13. Damaj, M.I., Patrick, G.S., Creasy, K.R., Martin, B.R., 1997. Pharmacology of lobeline, a nicotinic receptor ligand. J. Pharmacol. Exp. Ther. 282, 410-419.
14. de Fiebre, C.M., Meyer, E.M., Henry, J.C., Muraskin, S.I., Kem, W.R., Papke, R.L., 1995. Characterization of a series of anabaseine-derived compounds reveals that the 3-(4)-dimethylaminocinnamylidine derivative is a selective agonist at neuronal nicotinic α7/125I-α-bungarotoxin receptor subtypes. Mol. Pharmacol. 47, 164-171.
15. Decker, M.W., Majchrzak, M.J., Arneric, S.P., 1993. Effects of lobeline, a nicotinic receptor agonist, on learning and memory. Pharmacol. Biochem. Behav. 45, 571-576.
16. Decker, M.W., Buckley, M.J., Brioni, J.D., 1994. Differential effects of pretreatment with nicotine and lobeline on nicotine-induced changes in body temperature and locomotor activity in mice. Drug Dev. Res. 31, 52-58.
17. Decker, M.W., Bannon, A.W., Curzon, P., et al., 1997. ABT-089 [2-methyl-3(2-(s)-pyrrolidinylmethoxy)pyridine dihydrochloride]. 2. A novel cholinergic channel modulator with effects on cognitive performance in rats and monkeys. J. Pharmacol. Exp. Ther. 283, 247-258.
18. Fenster, C.P., Rains, M.F., Noerager, B., Quick, M.W., Lester, R.A.J., 1997. Influence of subunit composition on desensitization of neuronal acetylcholine receptors at low concentrations of nicotine. J. Neurosci. 17, 5747-5759.
19. Freedman, R., Coon, H., Myles-Worsley, M., et al., 1997. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc. Natl. Acad. Sci. (USA) 94, 587-592.
20. Giniatullin, R.A., Talantova, M., Vyskocil, F., 1997. Desensitization shortens the high quantal content end-plate current time course in frog muscle with intact cholinesterase. J. Physiol. (London) 502, 641-648.
21. 3H] dopamine release from mouse striatal synaptosomes and response to chronic 1-nicotine treatment. J. Pharmacol. Exp. Ther. 282, 32-43.
22. Hatsukami, D., Pentel, P.R., Jensen, J., Nelson, D., Allen, S.S., Goldman, A., Rafael, D., 1998. Cotinine-effects with and without nicotine. Psychopharmacology 135, 141-150.
23. Herzig, K.E., Callaway, E., Halliday, R., Naylor, H., Benowitz, N.L., 1998. Effects of cotinine on information processing in nonsmokers. Psychopharmacology 135, 127-132.
24. Hoffman, P.W., Ravindran, A., Huganir, R.L., 1994. Role of phosphorylation in desensitization of acetylcholine receptors expressed in Xenopus oocytes. J. Neurosci. 14, 4185-4195.
25. Jones, M.V., Westbrook, G.L., 1996. The impact of receptor desensitization on fast synaptic transmission. Trends Neurosci. 19, 96-101.
26. Katz, B., Thesleff, S., 1957. A study of the 'desensitization' produced by acetylcholine at the motor end-plate. J. Physiol. (London) 138, 63-80.
27. Khan, I.M., Yaksh, T.L., Taylor, P., 1994. Ligand specificity of nicotinic acetylcholine receptors in rat spinal cord: studies with nicotine and cytisine. J. Pharmacol. Exp. Ther. 270, 159-166.
28. Khiroug, L., Sokolova, E., Giniatullin, R., Afzalov, R., Nistri, A., 1998. Recovery from desensitization of neuronal nicotinic acetylcholine receptors of rat chromaffin cells is modulated by intracellular calcium through distinct 2nd messengers. J. Neurosci. 18, 2458-2466.
29. Kimura, I., 1998. Calcium-dependent desensitizing function of the postsynaptic neuronal type nicotinic acetylcholine receptors at the neuromuscular junction. Pharmacol. Ther. 77, 183-202.
30. Krause, R.M., Buisson, B., Bertrand, S., Corringer, P.J., Galzi, J.L., Changeux, J.P., Bertrand, D., 1998. Ivermectin: a positive allosteric effector of the α7 neuronal nicotinic acetylcholine receptor. Mol. Pharmacol. 53, 283-294.
31. Krusek, J., Zemkova, H., 1994. Effect of ivermectin on γ-aminobutyric acid-induced chloride currents in mouse hippocampal embryonic neurones. Eur. J. Pharmacol. 259, 121-128.
32. 2+ permeability, conductance, and gating of human α4β2 nicotinic acetylcholine receptors. J. Neurosci. 17, 9035-9047.
33. Leonard, S., Adams, C., Breese, C.R., et al., 1996. Nicotinic receptor function in schizophrenia. Schizophr. Bull. 22, 431-445.
34. Lin, N.H., Gunn, D.E., Ryther, K.B., et al., 1997. Structure-activity studies on ABT-089: an orally bioavailable 3-pyridyl ether cholinergic channel modulator with cognition enhancing properties. J. Med. Chem. 40, 385-390.
35. + efflux from mouse brain synaptosomes. J. Neurochem. 63, 2125-2135.
36. McKenna, D.G., Monteggia, L.M., Tourna, E., et al., 1997. Gain of function mutation of human α7 nAChR: Distinct pharmacology of h-α7V274T. Soc. Neurosci. Abstr. 23, 156.16.
37. Milone, M., Wang, H.L., Ohno, K., et al., 1997. Slow-channel myasthenic syndrome caused by enhanced activation, desensitization, and agonist binding affinity attributable to mutation in the M2 domain of the acetylcholine receptor α subunit. J. Neurosci. 17, 5651-5665.
38. Nooney, J.M., Peters, J.A., Lambert, J.J., 1992. A patch clamp study of the nicotinic acetylcholine receptor of bovine adrenomedullary chromaffin cells in culture. J. Physiol. (London) 455, 503-527.
39. Olale, F., Gerzanich, V., Kuryatov, A., Wang, F., Lindstrom, J., 1997. Chronic nicotine exposure differentially affects the function of human α3, α4, and α7 neuronal nicotinic receptor subtypes. J. Pharmacol. Exp. Ther. 283, 675-683.
40. Papke, R.L., 1993. The kinetic properties of neuronal nicotinic receptors: genetic basis of functional diversity. Prog. Neurobiol. 41, 509-531.
41. Papke, R.L., Craig, A.G., Heinemann, S.F., 1994. Inhibition of nicotinic acetylcholine receptors by bis (2,2,6,6-tetramethyl-4-piperidinyl) sebacate (Tinuvin 770), an additive to medical plastics. J. Pharmacol. Exp. Ther. 268, 718-726.
42. Papke, R.L., Bencherif, M., Lippiello, P., 1996. An evaluation of neuronal nicotinic acetylcholine receptor activation by quaternary nitrogen compounds indicates that choline is selective for the α7 subtype. Neurosci. Lett. 213, 201-204.
43. Papke, R.L., Thinschmidt, J.S., Moulton, B.A., Meyer, E.M., Poirier, A., 1997. Activation and inhibition of rat neuronal nicotinic receptors by ABT-418. Br. J. Pharmacol. 120, 429-438.
44. Partin, K.M., Patneau, D.K., Winters, C.A., Mayer, M.L., Buonanno, A., 1993. Selective modulation of desensitization at AMPA versus kainate receptors by cyclothiazide and concanavalin A. Neuron 11, 1069-1082.
45. Reavill, C., Walther, B., Stolerman, I.P., Testa, B., 1990. Behavioural and pharmacokinetic studies on nicotine, cytisine and lobeline. Neuropharmacology 29, 619-624.
46. Role, L.W., Berg, D.K., 1996. Nicotinic receptors in the development and modulation of CNS synapses. Neuron 16, 1077-1085.
47. Steinlein, O.K., Magnusson, A., Stoodt, J., et al., 1997. An insertion mutation of the CHRNA4 gene in a family with autosomal dominant nocturnal frontal lobe epilepsy. Hum. Mol. Genet. 6, 943-947.
48. Sullivan, J.P., Donnelly-Roberts, D., Briggs, C.A., et al., 1997. ABT-089 [2-methyl-3(2-(S)-pyrrolidinylmethoxy)pyridine]: I. a potent and selective cholinergic channel modulator with neuroprotective properties. J. Pharmacol. Exp. Ther. 283, 235-246.
49. Swope, S.L., Moss, S.J., Blackstone, C.D., Huganir, R.L., 1992. Phosphorylation of ligand-gated ion channels: a possible mode of synaptic plasticity. FASEB J. 6, 2514-2523.
50. Taylor, P., 1985. Ganglionic stimulating and blocking agents. In: Gilman, A.G., Goodman, L.S., Rail, T.W., Murad, F. (Eds.), Goodman and Gilman's The Pharmacological Basis of Therapeutics. Macmillan, New York, pp. 215-221.
51. Terry, A.V., Buccafusco, J.J., Jackson, W.J., Zagrodnik, S., Evans-Martin, F.F., Decker, M.W., 1996. Effects of stimulation or blockade of central nicotinic cholinergic receptors on performance of a novel version of the rat stimulus discrimination task. Psychopharmacology 123, 172-181.
52. Valenta, D.C., Downing, J.E.G., Role, L.W., 1993. Peptide modulation of ACh receptor desensitization controls neurotransmitter release from chicken sympathetic neurons. J. Neurophysiol. 69, 928-942.
53. Weiland, S., Witzemann, V., Villarroel, A., Propping, P., Steinlein, O., 1996. An amino acid exchange in the 2nd transmembrane segment of a neuronal nicotinic receptor causes partial epilepsy by altering its desensitization kinetics. FEBS Lett. 398, 91-96.
54. Wonnacott, S., 1997. Presynaptic nicotinic ACh receptors. Trends Neurosci. 20, 92-98.
55. Zoltewicz, J.A., Prokai-Tatrai, K., Bloom, L.B., Kem, W.R., 1993. Long range transmission of polar effects in cholinergic 3-arylidene anabaseines. Conformations calculated by molecular modelling. Heterocycles 35, 171-179.